



PRIOR AUTHORIZATION POLICY

POLICY: Hepatitis C – Vosevi Prior Authorization Policy

- Vosevi® (sofosbuvir/velpatasvir/voxilaprevir tablets – Gilead)

REVIEW DATE: 08/02/2023

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Vosevi is a direct-acting-antiviral (DAA) containing sofosbuvir, a nucleotide analog NS5B polymerase inhibitor, velpatasvir, a hepatitis C virus (HCV) NS5A inhibitor, and voxilaprevir, a HCV NS3/4A protease inhibitor.¹ It is indicated for the treatment of adults with **chronic HCV** with or without compensated cirrhosis who have:

- **Genotype 1, 2, 3, 4, 5, or 6** infection and have **previously been treated with an HCV regimen containing an NS5A inhibitor**;
- **Genotype 1a or 3** infection and who have **previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor**.

Additional benefit of Vosevi over Epclusa® (sofosbuvir/velpatasvir tablets/oral granules) was not shown in adults with genotype 1b, 2, 4, 5, or 6 infection previously treated with sofosbuvir without an NS5A inhibitor.¹ The recommended dosage of Vosevi is one tablet, taken orally, once daily (QD) with food for 12 weeks.

Guidelines

For the most up-to-date guideline information always refer to the American Association for the Study of Liver Diseases (AASLD) guidelines.³

Vosevi is recommended in in several circumstances in adults, mainly in patients who are direct-acting antiviral-experienced. Some of these recommendations are based

on very limited data and are not FDA-approved indications for Vosevi (e.g., retreatment with Vosevi in patients who have failed Vosevi in the past [one case report]).

- **Genotype 1 through 6 chronic HCV, ± compensated cirrhosis, treatment-experienced:**
 - Prior sofosbuvir-based treatment failure: Vosevi for 12 weeks; the addition of ribavirin is recommended in patients with genotype 3 HCV with compensated cirrhosis.
 - Prior Mavyret® (glecaprevir/pibrentasvir tablets and oral pellets) treatment failure: Vosevi for 12 weeks; the addition of ribavirin is recommended in patients with compensated cirrhosis.
 - Prior Zepatier® (elbasvir/grazoprevir tablets) treatment failure: Vosevi for 12 weeks; the addition of ribavirin is recommended in patients with compensated cirrhosis.
 - Prior Vosevi treatment failure: Vosevi + ribavirin for 24 weeks.
- **Kidney transplant, genotype 1 through 6 HCV, ± compensated cirrhosis, treatment-experienced:**
 - Prior direct-acting antiviral-failure: Vosevi ± ribavirin for 12 weeks; the addition of ribavirin should be considered for patients with compensated cirrhosis and multiple negative baseline characteristics.
- **Recurrent HCV post-liver transplantation, genotype 1 through 6 infection of the allograft, ± compensated cirrhosis, treatment-naïve:**
 - Prior direct-acting antiviral failure: Vosevi for 12 weeks is recommended; the addition of ribavirin should be considered for patients with compensated cirrhosis and multiple negative baseline characteristics.

Vosevi for 12 weeks is an alternative recommendation for treatment-naïve adults with genotype 3 HCV with compensated cirrhosis who have the Y93H resistance-associated substitution.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Vosevi. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Vosevi as well as the monitoring required for adverse events and efficacy, approval requires Vosevi to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Vosevi® (sofosbuvir/velpatasvir/voxilaprevir tablets (Gilead) is(are) covered as medically necessary when the following criteria is(are) met for fda-approved indication(s) or other uses with supportive evidence (if applicable):

FDA-Approved Indications

1. Chronic Hepatitis C Virus (HCV) Genotype 1b, 2, 4, 5, or 6. Approve for 12 weeks if the patient meets the following (A, B, C, and D):

A) Patient is ≥ 18 years of age; AND

B) Patient meets ONE of the following (i or ii):

i. Patient does not have cirrhosis; OR

ii. Patient has compensated cirrhosis (Child-Pugh A); AND

C) Patient had a prior null response, prior partial response, or relapse after prior treatment with an HCV direct-acting antiviral regimen containing an NS5A inhibitor; AND

Note: Examples of direct-acting antivirals that are, or contain, an NS5A inhibitor include: Daklinza (daclatasvir tablets), Epclusa (sofosbuvir/velpatasvir tablets/oral pellets), Harvoni (ledipasvir/sofosbuvir tablets/oral pellets), Mavyret (glecaprevir/pibrentasvir tablets/oral pellets), Viekira Pak (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets, co-packaged), Zepatier (elbasvir/grazoprevir tablets).

D) The medication is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician.

2. Chronic Hepatitis C Virus, Genotype 1a or 3. Approve for 12 weeks if the patient meets the following (A, B, C, and D):

A) Patient is ≥ 18 years of age; AND

B) Patient meets ONE of the following (i or ii):

i. Patient does not have cirrhosis; OR

ii. Patient has compensated cirrhosis (Child-Pugh A); AND

C) Patient meets ONE of the following (i or ii):

i. Patient had a prior null response, prior partial response, or relapse after prior treatment with an HCV direct-acting antiviral regimen containing an NS5A inhibitor; OR

Note: Examples of direct-acting antivirals that are, or contain, an NS5A inhibitor include: Daklinza (daclatasvir tablets), Epclusa (sofosbuvir/velpatasvir tablets/oral pellets), Harvoni (ledipasvir/sofosbuvir tablets/oral pellets), Mavyret (glecaprevir/pibrentasvir tablets/oral pellets), Viekira Pak (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets, co-packaged), Zepatier (elbasvir/grazoprevir tablets).

ii. Patient had a prior null response, prior partial response, or relapse after prior treatment with an HCV DAA regimen containing Sovaldi (sofosbuvir tablets/oral pellets) + a non-NS5A inhibitor; AND

Note: Examples of regimens that contain Sovaldi (sofosbuvir tablets/oral pellets) + a non-NS5A inhibitor include: Sovaldi + NS3 inhibitors (Olysio [simeprevir capsules], Victrelis [boceprevir capsules], or Incivek [telaprevir tablets]) or Sovaldi + ribavirin \pm pegylated interferon.

D) The medication is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician.

Other Uses with Supportive Evidence

- 3. Chronic Hepatitis C Virus (HCV) Genotype 1b, 2, 4, 5, or 6.** Approve for 12 weeks if the patient meets the following (A, B, C, and D):
- A)** Patient is ≥ 18 years of age; AND
 - B)** Patient meets ONE of the following (i or ii):
 - i. Patient does not have cirrhosis; OR
 - ii. Patient has compensated cirrhosis (Child-Pugh A); AND
 - C)** Patient had a prior null response, prior partial response, or relapse after prior treatment with an HCV DAA regimen containing Sovaldi (sofosbuvir tablets/oral pellets) + a non-NS5A inhibitor; AND
- Note: Examples of regimens that contain Sovaldi (sofosbuvir tablets/oral pellets) + a non-NS5A inhibitor include: Sovaldi + NS3 inhibitors (Olysio [simeprevir capsules], Victrelis [boceprevir capsules], or Incivek [telaprevir tablets]) or Sovaldi + ribavirin \pm pegylated interferon.
- D)** The medication is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician.
- 4. Patient Has Been Started on Vosevi.** Approve for an indication or condition addressed as an approval in the Recommended Authorization Criteria section (FDA-Approved Indications or Other Uses with Supportive Evidence). Approve the duration described above to complete a course therapy (e.g., a patient who should receive 12 weeks, and has received 3 weeks should be approved for 9 weeks to complete their 12-week course).

CONDITIONS NOT COVERED

Vosevi® (sofosbuvir/velpatasvir/voxilaprevir tablets (Gilead) is(are) considered experimental, investigational or unproven for ANY other use(s) including the following (this list may not be all inclusive; criteria will be updated as new published data are available):

- 1. Hepatitis C Virus (HCV) [any genotype], Combination with Any Other Direct-Acting Antivirals (DAAs).** Vosevi provides a complete antiviral regimen.
- 2. Life Expectancy Less Than 12 Months Due to Non-Liver Related Comorbidities.** According to the AASLD guidelines, patients with a limited life expectancy that cannot be remediated by HCV treatment, liver transplantation, or another directed therapy do not require antiviral treatment.³
- 3. Pediatric Patients (Age < 18 Years).** The safety and efficacy of Vosevi have not been established in pediatric patients < 18 years of age.¹

REFERENCES

1. Vosevi® tablets [prescribing information]. Foster City, CA: Gilead; November 2019.
2. Bourliere M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. *N Engl J Med*. 2017;376(22):214-2146.

3. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Testing, managing, and treating hepatitis C. Available at: <http://www.hcvguidelines.org>. Updated October 24, 2022. Accessed on July 24, 2023.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	08/03/2022
Annual Revision	No criteria changes.	08/02/2023

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2023 Cigna